ProShares UltraShort NASDAQ Biotechnology
3 hedge funds and large institutions have $50.2K invested in ProShares UltraShort NASDAQ Biotechnology in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 4 closing their positions.
16.22% less ownership
Funds ownership: 16.62% → 0.4% (-16%)
57% less funds holding
Funds holding: 7 → 3 (-4)
98% less capital invested
Capital invested by funds: $2.94M → $50.2K (-$2.89M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$49.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.49M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$652K |
| 3 |
IMC Chicago
Chicago,
Illinois
|
-$590K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$205K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $46.4K | +$49.2K | +1,181 | +118,100% |
|
2
Morgan Stanley
New York
| $2.1K | – | – | – |
|
3
Citigroup
New York
| $1.67K | – | – | – |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$1.49M | -29,433 | Closed |
|
|
5
Citadel Advisors
Miami,
Florida
| – | -$652K | -12,903 | Closed |
|
|
6
IMC Chicago
Chicago,
Illinois
| – | -$590K | -11,668 | Closed |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| – | -$205K | -4,062 | Closed |
|
BIS Hedge Fund Activity: Q4 2022 in Review
3 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q4 2022, worth a combined $50.2K — down 98% from $2.94M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BIS and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, adding an estimated $49.2K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $1.49M sold.
- 3 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q4 2022, down from 7 in Q3 2022.
- Funds reported $50.2K of ProShares UltraShort NASDAQ Biotechnology stock for Q4 2022, down 98% quarter-over-quarter.
- 0 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q4 2022 and 4 closed out, a net change of -4 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q4 2022 was UBS Group, an estimated $49.2K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q4 2022 was Susquehanna International Group, an estimated $1.49M sold.
Based on aggregated 13F filings for Q4 2022.